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Oral anticoagulation (OAC) is used to prevent stroke in patients with atrial fibrillation or heart 46 
valve disorders. However, OAC may cause haemorrhagic stroke. We completed a randomised 47 
trial of stroke secondary prevention [1], using primary care electronic health records (EHRs) 48 
collected into the UK Clinical Practice Research Datalink (CPRD). A small proportion of 49 
participants were prescribed warfarin following a haemorrhagic stroke diagnosis. The present 50 
research aimed to explain this observation. 51 
 52 
Participants were selected from all 11,391 patients with prevalent stroke, from 106 family 53 
practices in England and Scotland, included in the trial [1]. Patients were included if they had a 54 
record of haemorrhagic stroke before the trial and were treated with warfarin during the trial. 55 
Family physicians were sent a postal questionnaire asking respondents about the nature of the 56 
stroke suffered by the patient and indications for warfarin therapy. Type of stroke was coded 57 
using the International Classification of Diseases 10th Revision [2]. Warfarin accounts for 99% of 58 
OAC prescriptions in CPRD. The project was approved by external scientific and ethical review 59 
committee (ISAC protocol 08_083A2). GPs consented to their practice’s participation. Fully 60 
anonymised data were used and no patient consent was sought. 61 
 62 
There were 134 (1.2%) participants with EHRs documenting previous haemorrhagic stroke who 63 
were prescribed warfarin during the trial. The index stroke event was coded into the EHR as a 64 
sub-arachnoid haemorrhage for 25 (24%) of cases and as intracerebral haemorrhage (ICH) for 78 65 
(76%) of cases. There were 40 (47%) women and the mean age was 75 years (range 40 to 94 66 
years). Questionnaire responses were obtained for 103 (77%) patients with sufficient information 67 
to confirm the type of stroke obtained for 86 (64%) (Figure 1). 68 
 69 
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Questionnaire responses revealed that there were 41 (48%) patients with a physician-confirmed 70 
diagnosis of cerebral infarction (n=39) or other non-haemorrhagic stroke (n=2). The diagnosis 71 
was confirmed by imaging reports recorded for 36 (88%) of patients. There were five patients 72 
with a code for ischaemic stroke recorded after the initial haemorrhagic stroke but only two of 73 
these were within one year of the index stroke, possibly representing a clarification of the initial 74 
diagnosis. Indications for OAC in this group of participants included atrial fibrillation (n=27), 75 
disease of pre-cerebral and cerebral arteries (n=4), venous thromboembolism and other and not 76 
known (n=10). 77 
 78 
There were 45 patients with a physician-confirmed diagnosis of haemorrhagic stroke including 79 
sub-arachnoid haemorrhage (n=17) and ICH (n=28). The diagnosis was supported by imaging 80 
results for 38 (84%) patients. Indications for OAC therapy included atrial fibrillation (n=20), 81 
venous thrombosis (n=10), pulmonary embolism (n=5), aortic valve replacement (n=3), 82 
percutaneous coronary intervention, vasculitis and not known (n=7). 83 
 84 
We conclude that in the EHRs of a large population of stroke patients, there may be appreciable 85 
numbers with a diagnosis of haemorrhagic stroke who are treated with OAC therapy. We 86 
reported previously on the clinical coding of stroke in EHRs [3] and the potential for 87 
misclassification of stroke diagnoses. The present results should not be considered to evaluate 88 
the overall reliability of stroke coding in EHRs, because the sample was one in which data 89 
discrepancies were expected. 90 
 91 
In about half of patients, the stroke event was mis-coded as a haemorrhagic stroke when the 92 
physician-reported diagnosis for the same event date was one of cerebral infarction. 93 
4 
Misclassification might sometimes result from haemorrhagic transformation, which is not 94 
necessarily a contra-indication to OAC therapy. Physicians may draw on sources of data from 95 
outside the EHR. Nevertheless, it is concerning that appreciable numbers of stroke patients are 96 
prescribed OAC therapy with incorrect diagnostic information coded into their EHRs, with 97 
potential medico-legal implications. Improved information sharing between providers would be 98 
of benefit to physicians. 99 
 100 
A second group comprises patients with a confirmed diagnosis of haemorrhagic stroke who were 101 
treated with OAC therapy for co-existing thromboembolic disorders. This highlights the difficult 102 
balance of risks and benefits that may sometimes be required in clinical practice. However, the 103 
use of OAC therapy in patients with previous ICH remains controversial [4]. Improved evidence 104 
and decision support are required for these high-risk patients. 105 
 106 
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Figure 1 Legend: Flow chart showing physician-reported data for confirmed stroke type 122 
and indication for OAC therapy in 103 participants with electronic records for 123 
haemorrhagic stroke. 124 
125 
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 133 
11,391 participants with previous stroke 
included in point-of-care trial 
134 participants with electronic health 
record of previous haemorrhagic stroke 
and current warfarin prescription during 
trial intervention period 
103 participants with questionnaire 
response obtained  
86 participants with type of stroke 
determined by questionnaire 
11,263 not eligible 
31 did not provide responses 
17 excluded, insufficient 
information 
41 (48%) participants with physician-
confirmed diagnosis of cerebral infarction 
or other non-haemorrhagic stroke 
45 (52%) participants with physician-
confirmed diagnosis of sub-arachnoid 
haemorrhage (17) or intracerebral 
haemorrhage (28)  
Indications for OAC therapy include: 
atrial fibrillation (20); venous thrombosis 
(10); pulmonary embolism (5); aortic valve 
replacement (3); other and not known (7) 
Indications for OAC therapy include: atrial 
fibrillation (27); disease of pre-cerebral or 
cerebral arteries (4); venous 
thromboembolism, other and not known (10) 
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